Basic research for the autologous cancer vaccination- and radiation-combined therapy for urogenital cancers.

• Project/Area Number: 24791650
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: KOBAYASHI Yasuyuki 岡山大学, 大学病院, 助教 (50366027)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 前立腺癌 / 放射線治療 / ワクチン / 注入法 / 腫瘍 / 遺伝子治療 / REIC / 局所注入 / 尿路性器癌 / 放射線

Outline of Final Research Achievements

The first in-human clinical study, a Phase I/IIa study of in situ Ad-REIC gene therapy for prostate cancer, is currently performed in our department. Using the Ad-REIC as a new form of therapeutic cancer vaccine, the effects of autologous cancer vaccination via cancer-specific apoptosis and anticancer immune upregulation is evaluated as the therapeutic mechanism. On the other hands, the combination therapy with radiation and Ad-REIC agent could be promising for the treatment of progressive urogenital cancers. We herein conducted a basic research for the development of novel therapeutic methods. In addition, we performed the experiments as for a novel method for achieving widespread intratissue distribution of the infusate by permeating it in situ.